Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations
Rivaroxaban, a direct oral anticoagulant (DOAC), demonstrated greater efficacy and similar safety compared with warfarin in patients with chronic kidney disease and atrial fibrillation.
In patients hospitalized for ACS, early initiation of inclisiran may decrease risk for recurrent cardiovascular events.
Most patients recognize chest pain as MI symptom, but less than one-third recognize cold sweating, shortness of breath, radiating pain
Researchers sought to determine the relationship between pregnancy-induced hypertensive disorder and risk for heart failure.
In patients with chronic kidney disease, statin therapy can help slow progression of kidney dysfunction and decrease proteinuria.
New findings reported by Danish investigators are from the first study to demonstrate the association.
The 5-year number needed to treat to prevent the primary cardiovascular outcome 25 in patients with lower eGFR compared with 67 among those with normal eGFR.
Reduction seen in severity of pain and improvement in sleep quality for patients after open-heart surgery
Clinical trial demonstrates reduction in major adverse cardiovascular events of 20 percent, drug maker says
